Reglitazar
Basic information
- CAS
170861-63-9- Standard SMILES
Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2C(=O)NOC2=O)cc1- InChIKey
QBQLYIISSRXYKL-UHFFFAOYSA-N- Molecular formula
- C22H20N2O5
- Average molar mass
- 392.4 g/mol
- Monoisotopic mass
- 392.13722174
Overview
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Names & identifiers
- Preferred name
- Reglitazar
- IUPAC
- 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione
- English name
- 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]isoxazolidine-3,5-dione
- Molecular formula
- C22H20N2O5
- Molecular weight
- 392.4
Names & synonyms
Reglitazar170861-63-9JTT-501P9UTN18JVV4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dioneJTT 501JT-501JTT501DTXSID008701093,5-Isoxazolidinedione, 4-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-(4RS)-4-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy)benzyl)-3,5-isoxazolidinedione4-({4-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)-1,2-oxazolidine-3,5-dione
Show more names
PNU-716PNU182716PNU-182716JTT-501(Reglitazar)3,5-Isoxazolidinedione, 4-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]isoxazolidine-3,5-dione
4-((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)-1,2-oxazolidine-3,5-dioneREGLITAZARUMRefChem:879063JTT-501BETADTXCID00817933JT 501Reglitazar [INN]JTT-501.BETA.
Properties
Computed structural properties
- XLogP
- 4
- Topological polar surface area
- 90.7 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 6
- Rotatable bonds
- 7
- Heavy atoms
- 29
- Formal charge
- 0
- Complexity
- 572
Physicochemical properties
- FDA UNII
- 9 UTN18JVV · P9UTN18JVV
Chemistry & industry
Pharmacology
Pharmacodynamics
Reglixane shows a hypoglycemic effect and also a stronger triglyceride-lowering effect than the thiazolidine-2,4-diones. In preclinical studies, reglixane has been shown to prevent several diabetic complications, such as cataract, nephropathy, and neuropathy.
Mechanism of ActionReglixane is an agonist of peroxisome proliferator-activated receptor (PPAR) gamma and alpha.
Applications
UsesReglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels[1].
Upstream & downstream products
Upstream raw materials
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…